New Delhi, August 7, 2025: Medistep Healthcare Limited, a rapidly growing player in India’s pharmaceutical and healthcare market, has fixed the price of its upcoming Initial Public Offering (IPO) at Rs.43 per equity share. The offering comprises up to 37,44,000 equity shares with a face value of Rs.10 each. The IPO, which is being offered through a fixed price issue, will open for subscription on Friday, August 8, 2025, and close on Tuesday, August 12, 2025.
The lot size for the issue has been set at 3,000 equity shares. The shares are proposed to be listed on the Emerge Platform of National Stock Exchange of India Limited on August 18, 2025.
Of the total offer, not less than 17,79,000 equity shares are reserved for retail individual investors, not more than 17,76,000 equity shares are allocated for non-institutional investors, and 1,89,000 equity shares are reserved for the market maker portion. Fast Track Finsec Private Limited is acting as the lead manager to the issue, and Cameo Corporate Services Limited is the registrar.
Medisteps intends to raise approximately Rs 16.09 crore from the ipo. The net proceeds from the IPO will be utilised to fund capital expenditure towards the purchase of plant and machinery for expansion at the company’s existing manufacturing facility, to meet working capital requirements, to meet general corporate purposes and to meet out the Issue Expenses.
Founded in June 2023, Medistep Healthcare Limited is engaged in the manufacturing of sanitary pads and energy powders, and in the trading of pharmaceutical, nutraceutical, surgical, and intimate care products through an established distribution network. The company expanded its footprint in 2024 with the acquisition of the business of M/s MG Pharma, a proprietorship concern.
The company reported revenue from operations of Rs.4,965.48 lakh in FY25, compared to Rs.3,907.19 lakh in FY24. EBITDA stood at Rs.560 lakh for FY25, up from Rs.454.2 lakh in the previous year, while profit after tax (PAT) rose to Rs.414.42 lakh from Rs.332.76 lakh.
Following the issue, the company’s equity share capital will increase from 1,04,65,546 shares to 1,42,09,546 shares, with a post-issue implied market capitalization of Rs.61.10 crore.
Commenting on the IPO, Mr. Girdhari Lal Prajapati, Managing Director, Medistep Healthcare Limited, said, “The proceeds from the IPO will strategically support our expansion efforts and reinforce our footprint in both domestic and international markets. Our diversified and growing product portfolio positions us well to capitalize on the rising global and domestic demand for health and hygiene solutions.”
About Medistep Healthcare Limited:
Medistep Healthcare Limited was founded in 2023 and has strategically expanded its operations by acquiring the business of M/s MG Pharma in 2024, a proprietorship concern owned by one of its promoters, Ms. Prajapati Hetalben Girdharilal and founded in July 2018. The company has carved a niche in the healthcare industry through its expertise in manufacturing sanitary pads, energy powder and trading a diverse range of pharmaceutical products, nutraceutical products, intimate products and surgical products through a vast distribution network.
The company recorded revenue from operations of Rs 4965.48 lakhs in FY25, up from Rs 3907.19 lakhs in FY24. The company’s EBITDA grew from Rs 454.2 lakh in FY24 to Rs 560 lakh in FY25.
The company’s PAT grew from Rs 332.76 lakh in FY24 to Rs 414.42 lakh in FY25.
Disclaimer:
Medistep Healthcare Limited is proposing, subject to applicable regulatory approvals, to make an initial public offer of its Equity Shares and has filed the Red Herring Prospectus (“RHP”). The RHP has been filed with SEBI in accordance with Chapter IX of the SEBI (ICDR) Regulations, 2018; however, SEBI does not issue any observation on such documents. It is to be clearly understood that the permission by NSE should not be construed as approval or certification of the Offer Document or its contents. Investment in equity shares involves a high degree of risk, and investors are advised to read the RHP carefully, particularly the section on “Risk Factors,” before making any investment decision. The RHP and other documents related to the offer are available on the website of BRLM and the website of NSE and at Medistephc
